

JOANNA ADAMIEC-MROCZEK<sup>D</sup>, HANNA ZAJĄC-PYTRUS<sup>E</sup>, MARTA MISIUK-HOJŁO<sup>F</sup>

## Caspase-Dependent Apoptosis of Retinal Ganglion Cells During the Development of Diabetic Retinopathy

Department of Ophthalmology, Wroclaw Medical University, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of article; G – other

### Abstract

Diabetic retinopathy constitutes the most frequent cause of vision loss in professionally active individuals. Progressive impairment of visual acuity results from massive fibrovascular proliferation involving the fundus of the eye, as well as from the apoptosis of the neuronal structures of the retina. The results of many clinical studies, both on experimental models and on human material, confirmed evident enhancement of this process in the course of diabetes. The programmed cell death of retinal ganglion cells predominantly occurs secondarily to caspase-dependent intracellular processes. This paper presents evidence for the considerable involvement of the caspase-dependent mechanism of apoptosis of retinal ganglion cells in the early stages of retinal changes associated with progressive impairment of visual acuity. The authors emphasize the necessity of comprehensive understanding of mechanisms that underlie the programmed death of neural cells in the eyes of patients with diabetes. This clinical problem becomes of vital importance in view of the constantly increasing incidence of diabetes and severe impairment associated with the disorders of carbohydrate metabolism. Identification of a key component involved in this process would enable attempts oriented at pharmacological blockade of apoptosis in the retinal ganglion cells of patients with diabetes (*Adv Clin Exp Med* 2015, 24, 3, 531–535).

**Key words:** apoptosis, retinal ganglion cells, diabetic retinopathy, caspase.

Civilization progress is associated with unfavorable changes in the lifestyle of the majority of human population. Improper diet, rich in fat and carbohydrates, and simultaneous limitation of physical activity can lead to the development of a severe metabolic disorder, diabetes. According to WHO estimates, the worldwide population of patients with diabetes will reach 20 million by 2030 [1]. Diabetic retinopathy is one of the most frequent complications of diabetes. Apart from widely analyzed microangiopathic disorders, the problem of changes in the neural structure of the eye, i.e. retina, is highlighted with increasing frequency. Retinal ganglion cells are the predominant components that undergo injury [1, 2]. Improper metabolic processes are also observed within amacrine cells, astrocytes, and photoreceptor cells [3, 4]. The disorders associated with diabetes lead to irreversible changes in the abovementioned neural structures of the retina, mostly through a programmed cell death [5]. This is

reflected by markedly impaired perception of contrast and color which, together with accompanying microangiopathic complications, leads to progressive deterioration of visual acuity. These changes are irreversible as the neural cells are incapable of proliferation.

### Apoptosis Under Conditions of General Homeostasis

Programmed cell death ensures the maintenance of balance between the processes of cellular proliferation and death. Uncontrolled proliferation (e.g. in neoplasms) or loss of cells (e.g. in degenerative changes) can result from mutations or influence of external factors. Biochemical pathways of apoptosis activation can be extra- or intracellular, and caspase-dependent or caspase-independent [6].



diabetic retinopathy. Programmed death of human vascular endothelial cells was studied extensively and widely described. In contrast, little is known on the apoptotic changes taking place within the cells forming the neural structures of the retina. As early as in 1960s, Bloodworth et al. [13] suggested that high glycemia exerts toxic effect on the retinal neurons. While functional changes of the retinal ganglion cells were detected as early as after 2 weeks of diabetes, the microaneurysms characteristic for simple retinopathy developed not earlier than after 6 months [1]. Abnormalities documented on ERG were associated with impaired perception of contrast and prolonged dark adaptation time [14, 15]. Immunohistochemical examination of the retina from patients with diabetes revealed the presence of caspase-3 [16], caspase-9 [16], *Bax* [3, 17, 18], *Bad* [17, 18], and *Fas* [3] in retinal ganglion cells (RGCs). Enhanced release of cytochrome c and *AIF* was documented both in RGCs and in photoreceptor cells [3, 19]. Müller cells and astrocytes also seem to undergo activation in the course of diabetes, as confirmed by the activation and expression of factors associated with caspase-dependent mechanism of programmed cell death [20, 21].

Most available data originates from studies of experimental models. A study of rats exposed to streptozotocin (STZ) revealed that the apoptosis-specific changes in retinal ganglion cells were observed as early as after one month of diabetes-specific metabolic disorders [3, 5]. Li et al. [1] confirmed increased concentration of caspase-3 in the retina of rats as early as 2 weeks after the induction of STZ. The highest concentration of this active protein was documented after one month of disorders, and the peak levels of caspase-3 were detected in the ganglion cells, nerve fiber layer, and outer photoreceptor layer [1]. These findings were confirmed during another stage of the study, i.e. intra-vitreous injection of specific inhibitor of caspase-3, DEVD-CHO. The intensity of apoptotic processes in the retinal ganglion cells was significantly reduced as early as 2 weeks after the administration of the active substance [1].

Barber et al. [22] tried to quantify the degree of retinal ganglion cell atrophy. They analyzed paraffin-embedded retinal specimens from STZ-exposed rats, obtained after 30 weeks of experimentally induced diabetes. A 10% reduction in the total number of retinal ganglion cells was documented, along with a 22% decrease in the thickness of the inner ganglionic layer of the retina, and a 14% decrease in the thickness of the inner nuclear layer. Interestingly, no changes in the thickness of the outer ganglion cell layer were documented, which suggests that the processes of apoptosis are more intense within the inner layers of the retina [22].

Also studies based on the TUNEL reaction revealed changes in the inner retinal layers. RGCs and photoreceptor cells were the most commonly injured cellular types, which was reflected by the results of electrophysiological examination (ERG). Noticeably, these changes were not associated with diabetic retinopathy-specific vascular injury [3, 21].

A study of mice with a mutation of insulin encoding gene (so-called *Ins2<sup>Akita</sup>* mouse) revealed an increase in the concentration of caspase-3 after 4 weeks of diabetes-characteristic disorders [22]. Furthermore, a thinning of the inner retinal layers was observed after 22 weeks of the experiment [3]. Probably the changes documented in this experimental model also resulted from the caspase-dependent process of apoptosis. This is also suggested by OCT findings in patients with type 1 diabetes, in whom the reduced thickness of the inner retinal layers is associated with only minimal vascular lesions [24, 25].

Kowluru et al. [26] confirmed an increase in the cytosol concentration of cytochrome c, occurring secondarily to the activation of caspase system after 8 months of diabetes-specific metabolic disorders in STZ-exposed rats [3, 23]. The release of *cytochrome c* correlated with the transfer of *Bax* into the mitochondrion and initiation of apoptosis. This process can be inhibited *in vitro* through the reduction of superoxide concentration [3].

## Apoptosis of Retinal Ganglion Cells in Postmortem Examination of Humans

The aforementioned findings from experimental models were confirmed in histological material (retinal specimens) obtained *postmortem* from patients with diabetes [16]. All analyzed specimens were free from PDR-characteristic lesions. Fluoro-Jade B (FJB) was used as a marker of injured retinal ganglion cells. Interestingly, the presence of the active form of caspase-9 and enhanced expression of *Bax* were revealed in the injured areas of ganglion cell layer (GCL), resulting in further increase in the concentration of caspase-3. These findings seem confirmatory to the involvement of *Bax* and caspase-dependent mechanism of apoptosis in the neurodegeneration of the retina in patients with diabetes [16].

Important data from *postmortem* studies was published by Abu El-Asrar et al. [27]. They proved enhanced expression of caspase-3, *Fas*, and *Bax* in the retinal ganglion cells of patients with diabetes. Hyperglycemia induces *de novo* expression

of pro-apoptotic factor *Bad* in GCL. Simultaneously, the expression of factors inhibiting the process of apoptosis, such as *Akt* (protein kinase B), *Cox-2* (cyclooxygenase 2), and *Mcl-1*, was documented. *Akt* is a factor with confirmed protective effect on neural cells. This effect results from the influence of *Akt* on the synthesis of substances that regulate the life cycle of the cells [28]. The interaction between PI 3-kinase and *Akt* seems vital for this effect. Orike et al. [29] revealed that proper interaction between PI 3-kinase and *Akt* was a prerequisite of the survival of neural cells during an experimentally-induced deprivation of neurotrophic factors. A vital role of cooperation between these two factors was proved under hyperglycemic conditions: administration of insulin markedly reduced the number of retinal neural cells which underwent apoptosis, and this process was mediated by the activation of the PI 3-kinase/*Akt* system [30]. Furthermore, Abu El-Asrar et al. emphasized the association between the activation of the PI 3-kinase/*Akt* system and the increase in the cytoplasmic concentration of *Cox-2* in retinal ganglion cells, and in the cells of retinal pigment epithelium and ciliary body epithelium [28]. Enhanced expression of *Cox-2* is usually stimulated by such factors as bacterial lipopolysaccharides, pro-inflammatory cytokines, growth factors, hormones, and neoplastic cells. The effect of this factor is mediated by the synthesis of certain prostaglandins, including enhanced expression of apoptosis inhibitory factor *Mcl-1* via the activation of PI 3-kinase/*Akt* system. Furthermore, the authors of this study documented the presence of *Bad*, a pro-apoptotic factor released in response to hyperglycemia and oxidative stress. The concentration of *Bad* was highest in retinal ganglion cells, thus confirming the theory on the enhanced expression of

this factor in response to diabetes-induced neuronal injury. A similar response was observed in the course of neurotoxic injury of retinal ganglion cells, as well as during the transient retinal hypoxia associated with the occlusion of the central retinal artery [31].

Mitochondria are organelles which play a vital role in the process of apoptosis. Their regulatory function is associated with the ability to release pro-apoptotic factors, including cytochrome c and *AIF*. An increased concentration of cytochrome c and enhanced immunoreactivity of *AIF* were observed in *postmortem* retinal specimens.

Evidence presented in this paper, originating both from the experimental studies and from the examination of human *postmortem* material, unambiguously points to the involvement of apoptosis in the injury of retinal neuronal cells in patients with diabetes. However, the detailed pathogenic mechanism underlying the effects of hyperglycemia and associated oxidative stress remains unexplained. The presence of pro-apoptotic factors in retinal ganglion cells points to the predominant role of these compounds in the diabetic neurodegenerative disorders of the retina. This substantiates further efforts in search for a factor playing crucial role in the process of apoptosis of the retinal neural cells. Identification of such factors would raise a possibility of breaking the cascade of pathological reactions leading to atrophy of the retinal neural tissue.

Loss of vision in the course of diabetes is a growing worldwide problem of severe disability. The hereby presented metabolic pathway responsible for the injury of the organ of vision in the course of this condition undoubtedly constitutes a new target for clinical pharmacotherapy of diabetic retinopathy.

## References

- [1] Li YH, Zhuo YH, Lu L, Chen NY, Huang XH, Zhang JL, Li SY, Wang XG: Caspase dependent retinal ganglion cell apoptosis in the rat model of acute diabetes. *Chin Med* 2008, 121, 2566–2571.
- [2] Yang Y(1), Mao D, Chen X, Zhao L, Tian Q, Liu C, Zhou BL: Decrease in retinal neuronal cells in streptozotocin-induced diabetic mice. *Mol Vis* 2012, 18, 1411–1420.
- [3] Borrie SC, Duggan J, Cordeiro MF: Retinal cell apoptosis. *Expert Rev Ophthalmol* 2009, 4, 27–45.
- [4] Vujosevic S(1), Midena E: Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations. *J Diabetes Res* 2013, 2013, 905058.
- [5] Yang JH, Kwak HW, Kim TG, Han J, Moon SW, Yu SY: Retinal Neurodegeneration in Type II Diabetic Otsuka Long-Evans Tokushima Fatty Rats. *IOVS* 2013, 54, 3844–3851.
- [6] Barber A, Gardner T, Abcouwer S: The Significance of Vascular and Neural Apoptosis to the Pathology of Diabetic Retinopathy. *IOVS* 2011, 52, 1156–1163.
- [7] Korzeniewska-Dyl I: Caspases – a new target in inflammation and cancer therapy? *Pol Merk Lek* 2008, 139, 5–2 AUTOR?.
- [8] Fan TJ, Han LH, Cong RS, Liang J: Caspase family proteases and apoptosis. *Acta Biochim Biophys Sin* 2005, 37, 719–727.
- [9] Scorrano L, Korsmeyer SJ: Mechanisms of cytochrome c release by proapoptotic bcl-2 family members. *Biochem Biophys Res Commun* 2003, 304, 437–444.



- [10] Wei MC, Zong WX, Cheng EHY, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ: Proapoptotic bax and bak: a requisite gateway to mitochondrial dysfunction and death. *Science* 2001, 292, 727–730.
- [11] Sanges D, Comitato A, Tammaro R, Marigo V: Apoptosis in retinal degeneration involves cross-talk between apoptosis with inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors. *Proc Natl Acad Sci USA* 2006, 103, 17366–17371.
- [12] Marigo V: Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration. *Cell Cycle* 2007, 6, 652–655.
- [13] Bloodworth JM Jr: Diabetic retinopathy. *Diabetes* 1962, 11, 1–22.
- [14] Dosso AA, Yenice-Ustun F, Sommerhalder J, Golay A, Morel Y, Leuenberger PM: Contrast sensitivity in obese dyslipidemic patients with insulin resistance. *Arch Ophthalmol* 1998, 116, 1316–1320.
- [15] Ewing FM, Deary IJ, Strachan MW, Frier BM: Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. *Endocr Rev* 1998, 19, 462–476.
- [16] Oshitari T, Yamamoto S, Hata N, Roy S: Mitochondria- and caspase-dependent cell death pathway involved in neuronal degeneration in diabetic retinopathy. *Br J Ophthalmol* 2008, 92, 552–556.
- [17] Khalfaoui T, Basora N, Ouertani-Meddeb A: Apoptotic factors (Bcl-2 and Bax) and diabetic retinopathy in type 2 diabetes. *J Mol Hist* 2010, 41, 143–152.
- [18] Losiewicz MK, Fort PE: Diabetes impairs the neuroprotective properties of retinal alpha-crystallins. *IOVS* 2011, 52, 5034–5042.
- [19] Leal EC, Aveleira CA, Castilho AF, Serra AM, Baptista FI, Hosoya K, Forrester JV, Ambrósio AF: High glucose and oxidative/nitrosative stress conditions induce apoptosis in retinal endothelial cells by a caspase-independent pathway. *Exp Eye Res* 2009, 88, 983–991.
- [20] Cordeiro MF, Migdal C, Bloom P, Fitzke FW, Moss SE: Imaging apoptosis in the eye. *Eye* 2011, 25, 545–553.
- [21] Bringmann A, Wiedemann P: Muller glial cells in retinal disease. *Ophthalmologica* 2012, 227, 1–19.
- [22] Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, Gardner TW, Bronson SK: The Ins2Akita mouse as a model of early retinal complications in diabetes. *Invest Ophthalmol Vis Sci* 2005, 46, 2210–2218.
- [23] Bui BV, Loeliger M, Thomas M, Vingrys AJ, Rees SM, Nguyen CT, He Z, Tolcos M: Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. *Exp Eye Res* 2009, 88, 1076–1083.
- [24] van Dijk HW, Kok PHB, Garvin M: Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. *IOVS* 2009, 50, 3404–3409.
- [25] van Dijk HW, Verbraak FD, Kok PH: Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. *IOVS* 2010, 51, 3660–3666.
- [26] Kowluru RA, Abbas SN: Diabetes-induced mitochondrial dysfunction in the retina. *IOVS* 2003, 44, 5327–5334.
- [27] Abu El-Asrar AM, Dralands L, Missotten L, Al-Jadaan I, Geboes K: Expression of Apoptosis Markers in the Retinas of Human Subjects with Diabetes. *IOVS* 2004, 45, 2760–2766.
- [28] Abu El-Asrar AM, Dralands L, Missotten L, Geboes K: Expression of antiapoptotic and proapoptotic molecules in diabetic retinas. *Eye* 2007, 21, 238–245.
- [29] Orike N, Middleton G, Borthwick E, Buchman V, Cowen T, Davies AM: Role of PI3-Kinase, Akt and Bcl-2-related proteins in sustaining the survival of neurotrophic factor independent adult sympathetic neurons. *J Cell Biol* 2001, 154, 995–1005.
- [30] Barber AJ, Nakamura M, Wolpert EB, Reiter CE, Seigel GM, Antonetti DA, Gardner TW: Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. *J Biol Chem* 2001, 276, 32814–32821.
- [31] Rickman DW, Nacke RF, Rickman CB: Characterization of the cell death promoter, Bad, in the developing rat retina and forebrain. *Brain Res Dev Brain Res* 1999, 115, 41–47.

### Address for correspondence:

Joanna Adamiec-Mroczek  
Ophthalmology Department  
Wroclaw Medical University  
Borowska 213  
Wroclaw  
Poland  
Tel.: +48 71 733 11 00  
E-mail: j.adamiec@wp.pl

Conflict of interest: None declared

Received: 22.03.2014

Revised: 31.10.2014

Accepted: 8.05.2015